Oragenics Gross Profit vs Income Before Tax Analysis

OGEN Stock

USD 0.32 0.03 10.34%

Oragenics financial indicator trend analysis is much more than just breaking down Oragenics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oragenics is a good investment. Please check the relationship between Oragenics Gross Profit and its Income Before Tax accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oragenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.

Gross Profit vs Income Before Tax

Gross Profit vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oragenics Gross Profit account and Income Before Tax. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Oragenics' Gross Profit and Income Before Tax is 0.47. Overlapping area represents the amount of variation of Gross Profit that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Oragenics, assuming nothing else is changed. The correlation between historical values of Oragenics' Gross Profit and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit of Oragenics are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Gross Profit i.e., Oragenics' Gross Profit and Income Before Tax go up and down completely randomly.

Correlation Coefficient

0.47

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Oragenics minus its cost of goods sold. It is profit before Oragenics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Oragenics income statement and is an important metric when analyzing Oragenics profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most indicators from Oragenics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oragenics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oragenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.At this time, Oragenics' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 30th of November 2024, Enterprise Value is likely to grow to about 18 M, while Selling General Administrative is likely to drop about 4.2 M.

	2021	2022	2023	2024 (projected)
Interest Expense	15.8K	15.1K	30.6K	58.0K
Depreciation And Amortization	116.4K	44.7K	27.4K	26.0K

Interest Expense Depreciation And Amortization

Oragenics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Net Receivables	Short Term Debt	Current Deferred Revenue	Short Term Investments
Total Assets		-0.36	-0.31	0.96	0.61	-0.96	-0.4	0.16	0.98	0.2	0.98	0.34	0.28	-0.34	0.42	0.47	-0.25	0.31	0.98	0.67	0.27	-0.27	-0.25	-0.32	-0.43	-0.33
Other Current Liab	-0.36		0.62	-0.44	-0.05	0.43	0.28	-0.35	-0.33	-0.31	-0.33	-0.24	-0.32	0.6	-0.29	-0.32	0.6	-0.32	-0.3	-0.16	-0.15	0.56	0.71	0.58	0.59	-0.27
Total Current Liabilities	-0.31	0.62		-0.51	0.02	0.51	0.17	0.13	-0.32	0.0	-0.32	-0.21	-0.08	0.97	-0.03	-0.22	1.0	-0.04	-0.3	-0.2	0.07	0.99	0.65	0.99	0.87	-0.1
Total Stockholder Equity	0.96	-0.44	-0.51		0.55	-1.0	-0.33	0.03	0.97	0.09	0.97	0.28	0.19	-0.52	0.37	0.4	-0.47	0.21	0.97	0.67	0.21	-0.47	-0.35	-0.52	-0.57	-0.25
Property Plant And Equipment Net	0.61	-0.05	0.02	0.55		-0.54	-0.33	0.12	0.61	0.4	0.61	0.31	0.24	-0.06	0.1	0.34	0.11	0.28	0.61	0.57	0.18	0.08	-0.25	-0.01	-0.17	-0.18
Net Debt	-0.96	0.43	0.51	-1.0	-0.54		0.3	-0.04	-0.98	-0.08	-0.98	-0.26	-0.16	0.52	-0.35	-0.38	0.46	-0.18	-0.97	-0.7	-0.18	0.47	0.33	0.52	0.56	0.25
Retained Earnings	-0.4	0.28	0.17	-0.33	-0.33	0.3		-0.59	-0.27	-0.81	-0.27	-0.9	-0.91	0.35	-0.26	-0.99	0.12	-0.87	-0.29	-0.14	-0.69	0.2	0.53	0.23	0.53	0.53
Accounts Payable	0.16	-0.35	0.13	0.03	0.12	-0.04	-0.59		0.05	0.75	0.05	0.42	0.56	0.0	0.34	0.58	0.17	0.59	0.04	-0.08	0.35	0.08	-0.26	0.04	-0.14	-0.35
Cash	0.98	-0.33	-0.32	0.97	0.61	-0.98	-0.27	0.05		0.07	1.0	0.22	0.14	-0.32	0.37	0.34	-0.26	0.18	1.0	0.73	0.2	-0.27	-0.21	-0.33	-0.4	-0.28
Non Current Assets Total	0.2	-0.31	0.0	0.09	0.4	-0.08	-0.81	0.75	0.07		0.07	0.82	0.84	-0.2	0.06	0.79	0.05	0.84	0.06	0.04	0.49	-0.02	-0.39	-0.07	-0.29	-0.24
Cash And Short Term Investments	0.98	-0.33	-0.32	0.97	0.61	-0.98	-0.27	0.05	1.0	0.07		0.22	0.14	-0.32	0.37	0.34	-0.26	0.18	1.0	0.73	0.2	-0.27	-0.21	-0.33	-0.4	-0.28
Common Stock Total Equity	0.34	-0.24	-0.21	0.28	0.31	-0.26	-0.9	0.42	0.22	0.82	0.22		0.92	-0.41	-0.06	0.91	-0.17	0.89	0.22	0.25	0.69	-0.23	-0.46	-0.25	-0.48	-0.33
Common Stock Shares Outstanding	0.28	-0.32	-0.08	0.19	0.24	-0.16	-0.91	0.56	0.14	0.84	0.14	0.92		-0.28	0.03	0.9	-0.04	0.99	0.15	0.03	0.81	-0.09	-0.43	-0.11	-0.35	-0.23
Non Current Liabilities Total	-0.34	0.6	0.97	-0.52	-0.06	0.52	0.35	0.0	-0.32	-0.2	-0.32	-0.41	-0.28		0.02	-0.4	0.96	-0.24	-0.31	-0.21	-0.1	0.97	0.68	0.98	0.91	-0.01
Other Current Assets	0.42	-0.29	-0.03	0.37	0.1	-0.35	-0.26	0.34	0.37	0.06	0.37	-0.06	0.03	0.02		0.27	-0.01	-0.01	0.4	-0.01	-0.07	-0.03	-0.25	-0.05	-0.18	-0.29
Other Stockholder Equity	0.47	-0.32	-0.22	0.4	0.34	-0.38	-0.99	0.58	0.34	0.79	0.34	0.91	0.9	-0.4	0.27		-0.18	0.88	0.36	0.19	0.69	-0.25	-0.53	-0.28	-0.57	-0.54
Total Liab	-0.25	0.6	1.0	-0.47	0.11	0.46	0.12	0.17	-0.26	0.05	-0.26	-0.17	-0.04	0.96	-0.01	-0.18		0.0	-0.25	-0.15	0.08	0.99	0.62	0.98	0.84	-0.12
Property Plant And Equipment Gross	0.31	-0.32	-0.04	0.21	0.28	-0.18	-0.87	0.59	0.18	0.84	0.18	0.89	0.99	-0.24	-0.01	0.88	0.0		0.19	0.09	0.85	-0.05	-0.4	-0.08	-0.31	-0.22
Total Current Assets	0.98	-0.3	-0.3	0.97	0.61	-0.97	-0.29	0.04	1.0	0.06	1.0	0.22	0.15	-0.31	0.4	0.36	-0.25	0.19		0.69	0.23	-0.26	-0.21	-0.31	-0.39	-0.3
Common Stock	0.67	-0.16	-0.2	0.67	0.57	-0.7	-0.14	-0.08	0.73	0.04	0.73	0.25	0.03	-0.21	-0.01	0.19	-0.15	0.09	0.69		0.11	-0.15	-0.18	-0.2	-0.27	-0.19
Property Plant Equipment	0.27	-0.15	0.07	0.21	0.18	-0.18	-0.69	0.35	0.2	0.49	0.2	0.69	0.81	-0.1	-0.07	0.69	0.08	0.85	0.23	0.11		0.04	-0.25	0.04	-0.15	-0.22
Short Long Term Debt Total	-0.27	0.56	0.99	-0.47	0.08	0.47	0.2	0.08	-0.27	-0.02	-0.27	-0.23	-0.09	0.97	-0.03	-0.25	0.99	-0.05	-0.26	-0.15	0.04		0.62	0.99	0.87	-0.01
Net Receivables	-0.25	0.71	0.65	-0.35	-0.25	0.33	0.53	-0.26	-0.21	-0.39	-0.21	-0.46	-0.43	0.68	-0.25	-0.53	0.62	-0.4	-0.21	-0.18	-0.25	0.62		0.64	0.8	-0.08
Short Term Debt	-0.32	0.58	0.99	-0.52	-0.01	0.52	0.23	0.04	-0.33	-0.07	-0.33	-0.25	-0.11	0.98	-0.05	-0.28	0.98	-0.08	-0.31	-0.2	0.04	0.99	0.64		0.89	0.0
Current Deferred Revenue	-0.43	0.59	0.87	-0.57	-0.17	0.56	0.53	-0.14	-0.4	-0.29	-0.4	-0.48	-0.35	0.91	-0.18	-0.57	0.84	-0.31	-0.39	-0.27	-0.15	0.87	0.8	0.89		0.21
Short Term Investments	-0.33	-0.27	-0.1	-0.25	-0.18	0.25	0.53	-0.35	-0.28	-0.24	-0.28	-0.33	-0.23	-0.01	-0.29	-0.54	-0.12	-0.22	-0.3	-0.19	-0.22	-0.01	-0.08	0.0	0.21

Click cells to compare fundamentals

Oragenics Account Relationship Matchups

Oragenics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	19.8M	18.7M	28.2M	14.8M	5.0M	9.7M
Other Current Liab	334.2K	429.7K	92.6K	673.1K	230.7K	219.2K
Total Current Liabilities	1.9M	1.3M	1.4M	1.6M	1.8M	1.6M
Total Stockholder Equity	17.2M	16.8M	26.5M	13.0M	3.2M	3.0M
Property Plant And Equipment Net	914.7K	697.9K	523.6K	468.5K	9.8K	9.3K
Net Debt	(17.3M)	(16.7M)	(26.5M)	(10.8M)	(3.2M)	(3.3M)
Retained Earnings	(127.4M)	(154.4M)	(171.3M)	(185.6M)	(206.2M)	(195.9M)
Accounts Payable	1.2M	330.4K	855.0K	246.7K	1.2M	1.3M
Cash	18.3M	17.6M	27.3M	11.4M	3.5M	3.3M
Non Current Assets Total	914.7K	697.9K	523.6K	468.5K	1.1M	1.2M
Cash And Short Term Investments	18.3M	17.6M	27.3M	11.4M	3.5M	3.3M
Common Stock Total Equity	4.9K	29.4K	46.1K	91.8K	105.5K	110.8K
Common Stock Shares Outstanding	704.7K	942.2K	1.9M	2.0M	2.2M	2.4M
Liabilities And Stockholders Equity	19.8M	18.7M	28.2M	14.8M	5.0M	9.7M
Non Current Liabilities Total	670.7K	493.8K	299.5K	152.4K	137.2K	130.3K
Other Current Assets	570.1K	686.2K	434.7K	373.0K	382.3K	533.1K
Other Stockholder Equity	138.0M	164.0M	195.0M	197.0M	207.8M	218.2M
Total Liab	2.5M	1.8M	1.7M	1.7M	1.8M	1.8M
Property Plant And Equipment Gross	914.7K	697.9K	2.2M	1.8M	2.1M	2.2M
Total Current Assets	18.8M	18.0M	27.7M	14.3M	3.9M	3.7M
Accumulated Other Comprehensive Income	(1.6M)	(1.6M)	(1.7M)	0.0	(1.6M)	(1.7M)
Common Stock	46.1K	91.8K	116.4K	2.0K	3.1K	2.9K
Property Plant Equipment	92.0K	42.7K	523.6K	468.5K	421.7K	228.1K
Short Long Term Debt Total	979.7K	898.9K	797.2K	624.5K	322.5K	592.4K
Short Term Debt	309.0K	582.0K	497.7K	676.5K	322.5K	530.7K
Net Tangible Assets	10.7M	9.7M	23.8M	11.4M	13.1M	9.0M
Retained Earnings Total Equity	(101.4M)	(111.4M)	(127.4M)	(154.4M)	(139.0M)	(132.1M)
Capital Surpluse	101.4M	126.1M	138.0M	164.0M	188.6M	110.2M
Preferred Stock Total Equity	6.3M	6.1M	6.5M	7.2M	8.3M	8.7M
Non Currrent Assets Other	(914.7K)	(697.9K)	(523.6K)	(468.5K)	1.1M	1.1M
Short Long Term Debt	143.9K	228.2K	303.4K	267.6K	307.8K	164.1K
Net Invested Capital	10.9M	9.9M	24.1M	11.7M	13.4M	13.1M
Net Working Capital	17.0M	16.6M	26.3M	12.7M	14.6M	18.3M
Capital Stock	6.6M	7.3M	2.8M	1.6M	1.4M	1.4M

Pair Trading with Oragenics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oragenics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oragenics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Oragenics Stock

0.63

ELAN

Elanco Animal Health

Pair Corr

Moving against Oragenics Stock

0.71	BHC	Bausch Health Companies	Pair Corr
0.68	EWTX	Edgewise Therapeutics	Pair Corr
0.64	GILD	Gilead Sciences	Pair Corr
0.6	GANX	Gain Therapeutics	Pair Corr
0.54	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr

The ability to find closely correlated positions to Oragenics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oragenics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oragenics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oragenics to buy it.

The correlation of Oragenics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oragenics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oragenics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Oragenics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Oragenics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oragenics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oragenics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oragenics Stock:

How To Invest In Oragenics

Details

Is Oragenics Stock a good investment?

Details

What is Oragenics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oragenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.

You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oragenics. If investors know Oragenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oragenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.97)

Revenue Per Share

0.002

Quarterly Revenue Growth

(0.91)

Return On Assets

(2.20)

Return On Equity

(4.55)

The market value of Oragenics is measured differently than its book value, which is the value of Oragenics that is recorded on the company's balance sheet. Investors also form their own opinion of Oragenics' value that differs from its market value or its book value, called intrinsic value, which is Oragenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oragenics' market value can be influenced by many factors that don't directly affect Oragenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Oragenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oragenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oragenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oragenics Gross Profit vs Income Before Tax Analysis

Gross Profit vs Income Before Tax

Gross Profit vs Income Before Tax Correlation Analysis

Correlation Coefficient

Gross Profit

Income Before Tax

Oragenics fundamental ratios Correlations

Oragenics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oragenics fundamental ratios Accounts

Pair Trading with Oragenics

Moving together with Oragenics Stock

Moving against Oragenics Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Short Long Term Debt Total	+ 0.99	Total Current Liabilities
Short Term Debt	+ 0.99	Total Current Liabilities

Net Debt	- 1.0	Total Stockholder Equity
Other Stockholder Equity	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Total Current Assets	- 0.97	Net Debt
Net Debt	- 0.96	Total Assets